Novartis Venture Fund
Novartis Venture Fund is the corporate venture capital arm of Novartis AG, investing $5-25 million in early-stage life science companies developing novel therapeutics across North America and Europe, managing ~$750 million across 40+ portfolio companies since 1996.
- Company typePrivate
- Founded1996
- HeadquartersBasel, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Novartis Venture Fund does
Novartis Venture Fund (NVF) is the wholly-owned corporate venture capital arm of Novartis AG, founded in 1996 and headquartered in Basel, Switzerland with a regional office in Cambridge, Massachusetts. The fund invests across North America and Europe in life science companies developing novel therapeutics and platforms, with USD 750 million in committed capital deployed across more than 40 active portfolio companies. NVF primarily targets seed and Series A rounds with equity checks of USD 5-10 million (capacity up to USD 25 million per company) and participates selectively in later-stage rounds, often taking a board seat.
NVF's investment model combines financial return objectives with strategic value to Novartis: the team actively partners with portfolio company boards, offers access to Novartis's R&D, business development, and commercialization infrastructure, and has historically used portfolio holdings as a pipeline source for Novartis and peer pharma M&A. The investment team of roughly 15 professionals (Global Head, Managing Directors, Principals, Analysts, and Associates) is structured around drug development expertise — credentials include PhDs in physics, chemistry, biochemistry, molecular biology, immunology, and MD/MBA backgrounds, plus prior tenure at Novartis R&D, McKinsey, Pfizer Ventures, MPM Capital, Flagship Pioneering, and Allen & Overy.
Since inception NVF has taken over 70 portfolio companies to successful exit — nearly 40 via IPO and over 30 via M&A — with acquirers including Medtronic, Roche, Johnson & Johnson, Pfizer, AstraZeneca, Amgen, Takeda, AbbVie, GlaxoSmithKline, Merck, and Novartis itself. Revenue is generated through equity appreciation and exit proceeds rather than management fees in the conventional third-party fund sense; the fund is operated inside the Novartis AG corporate perimeter, with capital sourced from Novartis balance sheet.
Novartis Venture Fund firmographics
Firmographics- Name
- Novartis Venture Fund
- Legal name
- Novartis Venture Fund
- Website
- http://www.nvfund.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Novartis Venture Fund is the corporate venture capital arm of Novartis AG, investing $5-25 million in early-stage life science companies developing novel therapeutics across North America and Europe, managing ~$750 million across 40+ portfolio companies since 1996.
- Ownership category
- akta.pro rank
Novartis Venture Fund industry classification
Industry- Product category
- Life Science Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industries
- Early-Stage Venture Capital (Series A/B) (FSANAAAB), Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)
Keywords
Where Novartis Venture Fund is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Novartis Venture Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Revenue model
- Investment Returns: NVF generates returns through equity investments in portfolio companies. Returns are realized through IPO exits and M&A transactions when portfolio companies are acquired by pharmaceutical companies or go public.
Go-to-market motion2 records
Novartis Venture Fund product offering
Product offeringCore offering
Novartis Venture Fund is a corporate venture capital fund that provides equity financing to early-stage and growth-stage biotechnology and biopharmaceutical companies developing novel therapeutics and platforms. The fund invests primarily $5-10 million per company (up to $25 million) at seed and Series A stages, taking an active board role and offering strategic guidance alongside capital.
Product overview
Novartis Venture Fund is a life science venture capital fund that provides equity investment in biotechnology and biopharmaceutical companies across North America and Europe. The fund does not offer a unified product or platform but rather provides investment services and portfolio company support. The fund manages approximately USD 750 million in committed capital across more than 40 portfolio companies, with a focus on novel therapeutics and platforms at seed and Series A stages, though they remain open to later-stage opportunities.
Differentiator
Problem solved
Functional benefit
Products and services
- Novartis Venture Fund Investment Services
Companies that use Novartis Venture Fund
Customer profileSegments1 record
Ideal customer profiles1 record
Novartis Venture Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Novartis Venture Fund partnerships and signals
Strategic signalScale indicators7 records
Recent moves5 records
Expansion highlights5 records
Novartis Venture Fund competitors and assessment
Company assessmentDirect peers
- AbbVie Ventures: AbbVie's CVC arm investing across therapeutic areas. Closely comparable as a pharma CVC; relevant connection point - AbbVie acquired NVF-backed Capstan Therapeutics in 2025.
- Amgen Ventures: Amgen's corporate venture fund targeting early-stage biotech. Direct pharma-CVC peer; Amgen acquired NVF portfolio company Kinetix Pharmaceuticals (2004).
- Takeda Ventures: Takeda Pharmaceutical's CVC arm focused on life sciences. Direct comparable as pharma CVC; Takeda has been a frequent acquirer of NVF-backed companies (Intellikine, LigoCyte, Syrxx).
- Pfizer Ventures: The corporate venture capital arm of Pfizer, investing in early-stage life sciences companies. Directly comparable to NVF as another large pharma CVC writing equity checks in biotech/pharma with strategic intent and board participation.
- Johnson & Johnson Innovation (JJDC): J&J's corporate venture arm, actively investing in therapeutic startups across modalities. Overlaps directly with NVF in life science seed/Series A deals and was a co-lead on the Citryll €85M Series B alongside NVF.
- Roche Venture Fund: Swiss-headquartered pharma CVC of Roche, investing in early-stage therapeutics and diagnostics. Closely comparable to NVF given parallel geographic base (Basel) and overlapping portfolio exit history (Roche has been a serial NVF exit buyer via Inflazome, Arctos, Enterprise TMEM16A).
- SR One (GSK): GlaxoSmithKline's CVC investing in biotech and life sciences. Same mandate structure as NVF with sector focus and active board participation; comparable check sizes and stage orientation.
- Bristol-Myers Squibb Ventures: Bristol-Myers Squibb's corporate venture arm making equity investments in biotech/therapeutics. Direct competitor for pharma-aligned Series A/B deals with overlapping diligence network.
- Sanofi Ventures: Sanofi's strategic venture arm focused on innovative therapeutics. Direct peer as another big-pharma CVC competing for differentiated biotech at seed/Series A.
Broad incumbents
- MPM Capital: Dedicated, independent life sciences investment firm with significantly larger AUM than NVF. Comparable as a serious biotech investor; additionally, NVF Managing Director Laura Brass was previously a Managing Director at MPM, evidencing personnel overlap in the same funding ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Novartis Venture Fund social profiles
Digital presenceNovartis Venture Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novartis Venture Fund leadership team
Management profileNumber of profiles
Profiles18 records
Novartis Venture Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novartis Venture Fund M&A and investment
M&A and investmentM&A
Investments295 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novartis Venture Fund
What does Novartis Venture Fund do?
Novartis Venture Fund is a corporate venture capital fund that provides equity financing to early-stage and growth-stage biotechnology and biopharmaceutical companies developing novel therapeutics and platforms. The fund invests primarily $5-10 million per company (up to $25 million) at seed and Series A stages, taking an active board role and offering strategic guidance alongside capital.
Is Novartis Venture Fund a public or private company?
Novartis Venture Fund is a private company. It is classified as corporate owned and is currently operating.
When was Novartis Venture Fund founded?
Novartis Venture Fund was founded in 1996. It employs 11 to 50 people.
Where is Novartis Venture Fund based?
Novartis Venture Fund is headquartered in Basel, Switzerland, in the Europe region.
How does Novartis Venture Fund make money?
One revenue line is on record: investment Returns.
Who are Novartis Venture Fund's main competitors?
Direct peers on record are AbbVie Ventures, Amgen Ventures, Takeda Ventures, Pfizer Ventures, Johnson & Johnson Innovation (JJDC), Roche Venture Fund, SR One (GSK), Bristol-Myers Squibb Ventures and Sanofi Ventures. MPM Capital is listed as a broad incumbent.
Does Novartis Venture Fund have an API?
No public API is recorded for Novartis Venture Fund.
What industry is Novartis Venture Fund in?
Novartis Venture Fund's product category is Life Science Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.